Pfizer Inc. announced the acquisition of Global Blood Therapeutics to amplify the rare hematology and to brace the treatment for sickle cell disease. This agreement was finalized at the worth of USD 5.4 billion.
Biom’up announced the approval of Hemosnow by U.S. Food and Drug Administration . Hemosnow is a hemostatic dry powder for control the mild levels of bleeding during surgical procedures.
Author Credits: Radhika Gupta, Shivam Bhutani